IN THIS ISSUE .
November 18, 2009
Check out the Biomedical Beat Cool Image Gallery.
Got research news to share? E-mail us at firstname.lastname@example.org.
To change your subscription options or unsubscribe, visit https://public.govdelivery.com/accounts/USNIGMS/subscriber/new?topic_id=USNIGMS_3.
Subscribe to the RSS version of Biomedical Beat by selecting this XML link and following your news reader's instructions for adding a feed.
The National Institute of General Medical Sciences (NIGMS),
one of the National Institutes of Health, supports all research
featured in this digest. Although only the lead scientists
are named, coworkers and other collaborators also contributed
to the findings. To read additional news items, visit NIGMS
News, Twitter or Facebook. To check out free NIGMS publications, go to
the order form.
These six-month-old axolotls—a kind of salamander—glow green under blue light. That's because they were genetically modified to make harmless green fluorescent protein, or GFP. Like X-ray vision, GFP lets you see inside the axolotls as they hang out in their aquarium. GFP not only can reveal internal structures in living organisms, but it also can light up specific cells and even proteins within a cell. That allows scientists to identify and track things like cancer cells. GFP's abilities have made it one of the most useful tools in biomedical research and earned its discoverers a Nobel Prize. Courtesy of Jill Grossman, Jamison Hermann and Marc Zimmer, Connecticut College (music: "spinnin" by grapes).
Full story (Link no longer available)
More on GFP
Daughters aren't exactly like their mothers—at least when it comes to cell division in budding yeast. Every time a cell divides, it splits into a mother cell and a smaller daughter cell. Researchers previously thought that the same molecular mechanisms help the two prepare to divide again, but new work suggests otherwise. Rockefeller University molecular geneticist Frederick Cross and his team identified two daughter-specific proteins that control the daughters' size, also regulating the start of their cell division. The work may offer new insights into the normal and premature division of a wide range of cells, including cancer and stem cells.
University of Washington scientists have designed a better method to repair damaged hearts. Transplanted tissue containing just heart muscle cells hasn't worked well, mainly due to poor muscle survival. So, bioengineer Kelly Stevens and physician-scientist Chuck Murry created a human tissue patch that also contained cells resembling those lining and supporting blood vessels. Some were derived from human embryonic stem cells. This mix allowed the patches to form oxygen- and nutrient-delivering blood vessels. In rodents, the mixed-cell patches survived far better than the single-cell ones and performed more like human heart tissue. Similar mixes may hold promise for developing other regenerative therapies.
NIH's National Heart, Lung and Blood Institute and its National Institute of Diabetes and Digestive and Kidney Diseases also supported this work.
Most drugs work by binding a specific protein and blocking its activity. But a drug brushes up against thousands of other molecules in the body. These on- and off-target interactions determine a drug's therapeutic effect as well as its side effects. Now, a team of pharmaceutical scientists led by Bryan Roth of the University of North Carolina-Chapel Hill, and Brian Shoichet of the University of California, San Francisco, has predicted thousands of previously unknown drug-target associations using a computational method they developed. The new approach may help researchers predict side effects and find new uses for existing drugs.
NIH's National Institute of Mental Health, National Institute on Drug Abuse and National Institute on Aging also supported this work.
Mycobacterium tuberculosis, the bacterium that causes TB, manages to evade and subvert our immune defenses. Scientists led by Reuben Peters, a biochemist at Iowa State University, discovered that the bacterium produces a small molecule that saps the killing power of human immune cells. The researchers also may have found a way to counteract this bacterial strategy. This work could open a new avenue for combating tuberculosis, which has infected one-third of the world's population and is responsible for almost two million deaths annually.
NIH's National Institute of Allergy and Infectious Diseases also supported this work.